Metabolic dysfunction-associated steatohepatitis
Not yet recruitingStudy of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)
Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)
- Disease:Metabolic dysfunction-associated steatohepatitis
- Substances:–
Spain- Participants:18–64 years · 65+ years
- Sponsor:Glaxosmithkline Research & Development Limited











